TY - JOUR
T1 - Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience
AU - Kopylov, Uri
AU - Avni-Biron, Irit
AU - Ron, Yulia
AU - Koslowsky, Benjamin
AU - Waterman, Matti
AU - Daher, Saleh
AU - Ungar, Bella
AU - Schwartz, Doron
AU - Zittan, Eran
AU - Openhaim, Michal
AU - Yanai, Henit
AU - Maharshak, Nitsan
AU - Bar Gil Shitrit, Ariella
AU - Naftali, Timna
AU - Eliakim, Rami
AU - Chowers, Yehuda
AU - Ben-Horin, Shomron
AU - Dotan, Iris
N1 - Publisher Copyright:
© 2018 Editrice Gastroenterologica Italiana S.r.l.
PY - 2019/1
Y1 - 2019/1
N2 - Introduction: Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce. Aims: To describe the effectiveness and safety of VDZ in maintenance treatment of IBD. Methods: A multicenter retrospective national study. The primary outcome of was clinical response at week 52; main secondary aims included clinical remission at week 52, rates of secondary loss of response and treatment discontinuation. Results: We included 193 (133—CD; 60—UC) patients from 9 Israeli IBD centers. At week 52, response was observed in 62/133 (46.7%) CD patients, including 28 (21%) in clinical remission; 71 (53.3%) discontinued treatment or did not respond. For UC, response at week 52 was observed in 27/60 (45%), including 20 (33%) in clinical remission; 33 (55%) discontinued treatment or did not respond. Secondary non-response by week 52 occurred in 19.4% and 23.5% of week 14 responders in CD and UC, respectively. Week 14 response was associated with treatment continuation at week 52: no predictors of secondary loss of response were identified. VDZ is safe and effective for maintenance of response and remission in IBD; week 14 response is positively associated with long-term response in both UC and CD.
AB - Introduction: Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce. Aims: To describe the effectiveness and safety of VDZ in maintenance treatment of IBD. Methods: A multicenter retrospective national study. The primary outcome of was clinical response at week 52; main secondary aims included clinical remission at week 52, rates of secondary loss of response and treatment discontinuation. Results: We included 193 (133—CD; 60—UC) patients from 9 Israeli IBD centers. At week 52, response was observed in 62/133 (46.7%) CD patients, including 28 (21%) in clinical remission; 71 (53.3%) discontinued treatment or did not respond. For UC, response at week 52 was observed in 27/60 (45%), including 20 (33%) in clinical remission; 33 (55%) discontinued treatment or did not respond. Secondary non-response by week 52 occurred in 19.4% and 23.5% of week 14 responders in CD and UC, respectively. Week 14 response was associated with treatment continuation at week 52: no predictors of secondary loss of response were identified. VDZ is safe and effective for maintenance of response and remission in IBD; week 14 response is positively associated with long-term response in both UC and CD.
KW - Crohn's disease
KW - Ulcerative colitis
KW - Vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85054196809&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2018.07.040
DO - 10.1016/j.dld.2018.07.040
M3 - Article
C2 - 30172649
AN - SCOPUS:85054196809
SN - 1590-8658
VL - 51
SP - 68
EP - 74
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 1
ER -